Easily one of the top performers during the midweek session, shares of Rocket Pharmaceuticals (RCKT) – which specializes in curative gene therapies for diseases with high unmet needs – veritably soared, closing up nearly 39% against the prior day. Still, given the wild nature of RCKT stock, the underlying biotechnology firm has only gained about 11% for the year.
It then begs the question, which Rocket will show up moving forward? The one that can live up to its earlier promises or the iteration that has gone absolutely nowhere since making its public market debut in in early 2015? By looking at the face-value implications of its unusual stock options volume, a lay observer may come away with the impression that RCKT stock will go on a northward trajectory.
